🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

Altimmune, Inc. ALT R2KR3KPHARMA

Healthcare · Biotechnology · United States
Financial distress score 53/100 (Weak) — see indicators →
https://altimmune.com
Company Profile ↓
$2.12
-43.32% 1Y
Mkt Cap$412.38M
P/E-2.79
P/B1.07
52W High$6.18
52W Low$2.12
Book Value$2.44
EPS (TTM)$-0.76

Company Overview

Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.

Why Investors Should Care

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.08.

Recent Developments

  • Dec 2025 Revenue of $41.00K (+105.0% YoY); net profit $-88.09M.
  • Trailing 12 Months Year-on-year growth — revenue +105.0%.
  • 5-Year Trend Long-term compounding — revenue CAGR -46.4%.

Growth & Price Performance

Compounded Sales Growth

5 Years:-46.41%
1 Year:105.00%

Stock Price Performance

1 Year:-43.32%
6 Months:-25.61%
3 Months:-28.38%
1 Month:-30.26%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 0% of range
$2.12 $6.18
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • RSI (14)23.22 · Oversold
Price Performance
1M-30.26%
3M-28.38%
6M-25.61%
1Y-43.32%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

No notable strengths flagged.

CONS

  • Revenue declined at -46.4% CAGR over 5 years.
  • Trading 65.7% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).
  • RSI at 23 suggests oversold conditions.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-2.79
Industry PE
25.45
Forward P/E
-3.17
PEG Ratio
32.62
Book Value
$2.44
Price to Book
1.07
P/S
16,377.14
EV/EBITDA
-2.30
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
-46.41%
Profit 5Y
-
Revenue (YoY)
105.00%
Earnings (YoY)
-

Profitability & Returns

ROCE
-35.67%
ROE
-28.88%
ROA
-17.20%
Profit Margin
0.00%
Op Margin
-
Gross Margin
0.00%
EPS (Latest Qtr)
$-0.18
EPS (TTM)
$-0.76

Balance Sheet & Liquidity

Debt/Equity
0.08
Quick Ratio
26.37
Current Ratio
26.78
Debt
$36.02M
Total Assets
$335.63M
Current Assets
$334.68M
Working Capital
$263.19M

Ownership

Promoter Holding
0.43%
Chg in Prom Hold
0.02%
FII / Inst Holding
77.86%
Chg in FII Hold
0.01%

Financial Snapshot

Enterprise Value
$412.38M
Total Revenue (TTM)
$31.00K
EBITDA
$-98.63M
Free Cash Flow
$-48.79M
Operating Cash Flow
$-76.51M
Shares Outstanding
194.52M
Gross Margin
0.00%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 ALT Altimmune, Inc. R2KR3KPHARMA 2.12 -2.79 $412.38M 0.00% -35.67% -28.88% -46.41% -
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,273.46 42.83 $1.14T 0.60% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 263.81 30.60 $635.76B 1.98% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 285.64 80.69 $504.76B 2.54% 10.47% -129.24% 1.75% -29.06%
5 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 418.09 26.85 $375.28B 2.47% 9.74% 14.15% 10.40% 5.43%
6 MRK Merck & Co., Inc. SPXR3KPHARMA 145.27 116.22 $358.41B 2.31% - 6.96% 5.64% 10.01%
7 NVS Novartis AG PHARMA 151.12 22.83 $287.24B 3.36% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 171.49 25.63 $265.96B 2.00% 15.97% 21.96% 9.82% 45.96%
9 TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA 673.82 36.30 $249.14B 0.29% 8.14% 13.51% 8.81% 12.95%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Jun 2014Sep 2014Dec 2014Mar 2015Jun 2015Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Mar 2018Jun 2018Sep 2018Mar 2019Jun 2019Sep 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue ------------3.04M4.59M2.69M2.42M2.63M2.96M1.63M643.98K2.21M721.64K2.94M838.00K137.00K158.00K32.00K8.00K2.00K------5.00K5.00K5.00K26.00K0
Cost of Revenue ----------------------------------------
Gross Profit ----------------------------------------
Operating Expenses -----------------------------------21.82M22.93M20.86M28.92M24.24M
Operating Income -1.17M-4.00M-2.62M1.16M-1.96M-1.66M-940.47K-1.25M-1.60M-4.79M-5.51M-4.52M-4.01M-30.95M-5.99M-5.44M-4.06M-2.33M-3.55M-11.27M-7.31M-18.42M-18.32M-14.86M-24.86M-33.20M-19.50M-20.39M-24.75M-21.76M-18.01M-22.54M-26.79M-26.75M-24.77M-21.82M-22.92M-20.86M-28.89M-24.24M
EBITDA ------------------------------------20.23M-21.85M-18.49M-26.46M-21.47M
Interest Expense -----------------------------------1.00K264.00K495.00K876.00K1.07M
Pretax Income ------------------------------------20.26M-22.15M-19.01M-27.36M-22.56M
Tax Provision ------------------------------------681.00K0000
Net Income -439.12K-4.63M-2.63M1.46M-2.34M-1.32M-1.24M-1.23M-1.62M-4.80M77.80M-4.58M-3.11M-29.91M-3.17M-9.14M-2.35M-2.10M-3.39M-10.94M-3.89M-16.77M-17.77M-14.86M-24.83M-33.51M-19.43M-20.11M-23.52M-20.07M-16.06M-20.67M-24.39M-24.64M-22.84M-19.57M-22.15M-19.01M-27.36M-22.56M
Diluted EPS -0.01-0.08-0.040.02-0.04-0.02-0.02-0.020.121.671.15------------0.54-0.38-0.60-0.81-0.44-0.42-0.48-0.40-0.32-0.39-0.34-0.35-0.32-0.26-0.27-0.21-0.27-0.18
R&D Expense 2.37M1.73M-1.61M1.22M1.13M-1.03M1.38M2.40M-2.79M5.25M5.91M5.75M4.92M4.73M3.22M2.95M8.73M7.19M16.59M17.04M11.88M13.27M29.21M15.10M15.99M20.26M17.25M13.25M18.39M21.49M21.16M19.80M15.83M17.24M14.96M-16.19M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 20.99M24.27M----3.24M10.74M10.33M5.80M8.19M--68.00K426.00K20.00K41.00K
Cost of Revenue ----------------
Gross Profit ----------------
Operating Expenses ------------87.67M83.94M103.19M94.53M
Operating Income -23.55M-11.73M-6.27M-10.84M-10.19M-3.40M-11.09M-52.05M-42.83M-21.46M-54.80M--87.74M-83.51M-103.17M-94.49M
EBITDA -------------84.41M-87.94M-94.81M-87.03M
Interest Expense ------------8.00K35.00K9.00K1.64M
Pretax Income -------------84.91M-88.45M-95.06M-88.77M
Tax Provision -------------197.00K00-681.00K
Net Income -34.85M-3.80M-4.92M-11.72M-9.96M-3.44M-11.09M-46.43M-39.17M-20.52M-49.04M--84.71M-88.45M-95.06M-88.09M
Diluted EPS -----0.17-0.052.95----1.91--1.81-1.66-1.34-1.00
R&D Expense 20.88M21.22M19.51M15.29M9.32M5.13M7.22M18.41M18.46M17.77M49.77M74.54M70.54M65.80M82.23M66.43M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets -27.20M22.80M22.74M17.14M21.98M19.86M38.40M63.03M54.75M54.06M245.12M-206.93M210.64M139.31M279.93M
Current Assets -------------192.81M209.63M137.25M278.19M
Cash & Equivalents 2.67M11.79M11.24M12.70M10.48M18.64M15.57M2.88M8.77M33.72M8.96M115.92M-111.10M135.12M36.93M43.76M
Inventory -----------------
Receivables -------------173.00K1.11M544.00K1.22M
Total Liabilities -14.99M6.95M11.07M9.80M3.70M3.21M6.19M14.35M6.44M8.54M19.24M-21.64M16.54M15.80M55.04M
Current Liabilities -6.16M4.62M7.49M6.80M2.58M2.18M5.47M3.84M4.53M3.92M12.02M-17.05M12.14M10.47M15.00M
Long Term Debt ---1.70M730.28K---599.93K1.85M1.86M1.83M----34.29M
Total Debt -------------1.12M671.00K1.68M35.69M
Total Equity 3.15M12.21M15.85M11.67M7.34M18.27M43.13M32.21M39.40M48.31M45.52M225.88M-185.29M194.10M123.51M224.89M
Shares Outstanding -------------49.20M70.68M72.35M110.88M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -14.86M-7.81M-2.32M-----20.21M-9.39M-9.60M-34.31M--62.59M-75.81M-79.85M-67.53M
Investing Cash Flow 2.76M1.69M67.40K----13.73M-1.00M-28.29M-72.23M--73.40M13.73M-28.39M-132.47M
Financing Cash Flow 21.46M5.78M3.72M----15.84M32.49M12.53M213.49M-56.78M86.11M10.04M206.84M
Capital Expenditure -374.58K-71.44K--84.58K-92.27K-86.51K-124.95K-112.44K-975.41K-1.23K-203.96K-12.31M-126.00K-47.00K--11.00K
Free Cash Flow -15.24M-7.88M------20.33M-10.36M-9.60M-34.51M--62.71M-75.86M-79.85M-67.55M
Net Change in Cash -------------79.20M24.03M-98.19M6.83M

Ratios (Annual)

Figures in %.

Metric Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % ----------------
Operating Margin % -112.2%-48.3%-----342.7%-484.7%-414.6%-370.0%-669.5%-129,029.4%-19,603.3%-515,860.0%-230,461.0%
Net Margin % -166.0%-15.6%-----342.6%-432.3%-379.2%-353.7%-599.2%-124,577.9%-20,762.2%-475,295.0%-214,861.0%
ROE % -285.4%-24.0%-42.1%-159.7%-54.5%-8.0%-34.4%-117.8%-81.1%-45.1%-21.7%--45.7%-45.6%-77.0%-39.2%
ROCE % -112.0%-64.5%-41.1%-104.8%-52.5%-19.2%-33.7%-87.9%-85.3%-42.8%-23.5%--46.2%-42.1%-80.1%-35.7%

Shareholding Pattern

Insiders
0.43%
Institutions
77.86%
Public Float
78.20%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 10.48% 20.39M $53.21M
2 Deep Track Capital, Lp 9.90% 19.25M $50.24M
3 State Street Corporation 6.22% 12.10M $31.58M
4 TCG Crossover Management, LLC 5.14% 10.00M $26.10M
5 Vanguard Capital Management LLC 4.20% 8.18M $21.34M
6 Vanguard Portfolio Management LLC 3.77% 7.33M $19.13M
7 Marshall Wace LLP 3.52% 6.84M $17.86M
8 Viking Global Investors, L.P. 3.44% 6.70M $17.49M
9 RA Capital Management, L.P. 3.34% 6.50M $16.96M
10 Geode Capital Management, LLC 2.58% 5.01M $13.08M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ALT

Yahoo Finance Mon, 19 Oct 2026

Altimmune to Present New Data on Pemvidutide in Serious Liver Diseases at AASLD The Liver Meeting® 2026

Clinical highlights from the IMPACT Phase 2b study of pemvidutide in MASH demonstrated improvements in liver fibrosis and inflammation with generally favorable gastrointestinal tolerability Oral presentation to feature new pre-clinical data…

Yahoo Finance hu, 01 Oct 2026

Altimmune Details Pemvidutide’s Path Toward a Liver-Disease Franchise

Altimmune (NASDAQ:ALT) executives outlined the company’s strategy to build a liver-disease franchise around pemvidutide, a dual glucagon/GLP-1 agonist being developed for metabolic dysfunction-associated steatohepatitis, or MASH, alcohol us…

Yahoo Finance Wed, 23 Sep 2026

Altimmune to Participate in Stifel Cardiometabolic Forum

GAITHERSBURG, Md., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate …

Yahoo Finance ue, 22 Sep 2026

VKTX, GPCR, ALT Stocks Rise: Novo Nordisk Signals Bigger M&A As It Chases Over 5 ‘Multi-Blockbusters’

Novo targets over $23 billion in risk-adjusted pipeline sales by 2035, excluding any contribution from future acquisitions.

Yahoo Finance Fri, 11 Sep 2026

Why Is Altimmune (ALT) Up 14.2% Since Last Earnings Report?

Altimmune (ALT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo Finance ue, 08 Sep 2026

Altimmune’s (ALT) Three Liver Trials Move Forward At Once

On August 12, Altimmune (NASDAQ:ALT) reported second quarter results that read less like a routine earnings update and more like a status check on three separate diseases at the same time. The clinical-stage biopharmaceutical company disclo…

ALT — Frequently Asked Questions

What is the current share price of Altimmune, Inc. (ALT)?

As of 2026-10-23 16:27 PDT, Altimmune, Inc. (ALT) trades at $2.12 on NasdaqGM. Its 52-week range is $2.12 to $6.18.

What is the market capitalisation of ALT?

Altimmune, Inc. (ALT) has a market capitalisation of $412.38M on NasdaqGM.

What is the P/E ratio of ALT?

ALT trades at a trailing price-to-earnings (P/E) ratio of -2.79. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 1.07.

What is the return on equity (ROE) of ALT?

ALT has a return on equity (ROE) of -28.88%. Its return on capital employed (ROCE) is -35.67%.

Is ALT a good stock to buy?

This page provides a data-driven analysis of Altimmune, Inc. (ALT), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space